| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urinary Tract Infections | 8 | 2019 | 534 | 3.05 | Why? |
| Urinalysis | 3 | 2018 | 218 | 1.82 | Why? |
| Anti-Bacterial Agents | 24 | 2021 | 10083 | 1.69 | Why? |
| Primary Health Care | 20 | 2021 | 4839 | 1.46 | Why? |
| Parietal Lobe | 2 | 2018 | 29 | 1.45 | Why? |
| Memory Disorders | 3 | 2018 | 190 | 1.38 | Why? |
| Oseltamivir | 2 | 2020 | 583 | 1.16 | Why? |
| Atrophy | 2 | 2018 | 192 | 0.86 | Why? |
| Doxycycline | 2 | 2021 | 307 | 0.77 | Why? |
| Urine | 2 | 2018 | 469 | 0.72 | Why? |
| Respiratory Tract Infections | 13 | 2021 | 6817 | 0.72 | Why? |
| Pyuria | 1 | 2017 | 3 | 0.71 | Why? |
| Alzheimer Disease | 2 | 2018 | 1020 | 0.70 | Why? |
| Bacteriuria | 1 | 2017 | 31 | 0.69 | Why? |
| Practice Patterns, Physicians' | 7 | 2019 | 4927 | 0.65 | Why? |
| Gray Matter | 1 | 2018 | 150 | 0.65 | Why? |
| Floxacillin | 1 | 2016 | 14 | 0.65 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 350 | 0.63 | Why? |
| Drug Utilization | 4 | 2018 | 619 | 0.60 | Why? |
| Prescriptions | 1 | 2016 | 258 | 0.55 | Why? |
| Acne Vulgaris | 1 | 2016 | 198 | 0.52 | Why? |
| General Practitioners | 4 | 2018 | 568 | 0.51 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.44 | Why? |
| Inappropriate Prescribing | 3 | 2018 | 284 | 0.42 | Why? |
| Drug Prescriptions | 5 | 2019 | 1062 | 0.41 | Why? |
| Point-of-Care Systems | 3 | 2018 | 2955 | 0.40 | Why? |
| Patient-Centered Care | 1 | 2018 | 860 | 0.39 | Why? |
| Influenza, Human | 6 | 2021 | 10779 | 0.38 | Why? |
| Budesonide | 2 | 2021 | 192 | 0.38 | Why? |
| Amoxicillin | 3 | 2017 | 98 | 0.37 | Why? |
| Mental Recall | 2 | 2018 | 77 | 0.35 | Why? |
| Referral and Consultation | 3 | 2021 | 4816 | 0.34 | Why? |
| Bacterial Infections | 5 | 2021 | 2229 | 0.33 | Why? |
| United Kingdom | 11 | 2021 | 18046 | 0.32 | Why? |
| Drug Resistance, Bacterial | 4 | 2019 | 1414 | 0.30 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.28 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.28 | Why? |
| Prescription Drugs | 2 | 2018 | 243 | 0.27 | Why? |
| Europe | 10 | 2021 | 12702 | 0.24 | Why? |
| Patient Preference | 2 | 2021 | 750 | 0.24 | Why? |
| Minimal Clinically Important Difference | 1 | 2021 | 39 | 0.23 | Why? |
| Armenia | 1 | 2021 | 89 | 0.23 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.23 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 2 | 2018 | 72 | 0.22 | Why? |
| Cost-Benefit Analysis | 4 | 2018 | 2259 | 0.22 | Why? |
| Netherlands | 3 | 2021 | 3533 | 0.21 | Why? |
| Randomized Controlled Trials as Topic | 8 | 2021 | 10649 | 0.20 | Why? |
| Intention to Treat Analysis | 1 | 2021 | 673 | 0.20 | Why? |
| Nitrofurantoin | 1 | 2018 | 14 | 0.19 | Why? |
| Trimethoprim | 1 | 2018 | 22 | 0.19 | Why? |
| Anti-Infective Agents, Urinary | 1 | 2018 | 27 | 0.19 | Why? |
| Bacteria | 3 | 2019 | 1897 | 0.19 | Why? |
| Adaptive Clinical Trials as Topic | 1 | 2018 | 54 | 0.19 | Why? |
| Acute Kidney Injury | 1 | 2019 | 5762 | 0.19 | Why? |
| Headache | 2 | 2020 | 2257 | 0.18 | Why? |
| Medical Records Systems, Computerized | 1 | 2020 | 159 | 0.18 | Why? |
| Pamphlets | 1 | 2018 | 27 | 0.18 | Why? |
| Urinary Tract Physiological Phenomena | 1 | 2017 | 2 | 0.18 | Why? |
| Trypanocidal Agents | 1 | 2017 | 19 | 0.18 | Why? |
| Belgium | 2 | 2021 | 2064 | 0.18 | Why? |
| Penicillins | 1 | 2019 | 132 | 0.18 | Why? |
| Nonprescription Drugs | 1 | 2018 | 78 | 0.17 | Why? |
| Memory | 1 | 2018 | 137 | 0.17 | Why? |
| Economics | 1 | 2019 | 196 | 0.17 | Why? |
| Tenofovir | 1 | 2021 | 449 | 0.17 | Why? |
| Humans | 55 | 2021 | 930598 | 0.17 | Why? |
| Female | 27 | 2021 | 380317 | 0.16 | Why? |
| Cost Savings | 1 | 2019 | 296 | 0.16 | Why? |
| Poland | 2 | 2021 | 2368 | 0.16 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.16 | Why? |
| Aged | 17 | 2021 | 215776 | 0.16 | Why? |
| Quinazolinones | 1 | 2017 | 135 | 0.16 | Why? |
| Clarithromycin | 1 | 2017 | 112 | 0.16 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.15 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.15 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.15 | Why? |
| Male | 25 | 2021 | 367725 | 0.15 | Why? |
| Drug Costs | 1 | 2019 | 313 | 0.15 | Why? |
| Glucocorticoids | 2 | 2021 | 4431 | 0.14 | Why? |
| Physicians, Primary Care | 1 | 2018 | 298 | 0.14 | Why? |
| Wales | 1 | 2017 | 758 | 0.14 | Why? |
| Greece | 1 | 2021 | 2091 | 0.14 | Why? |
| Education, Medical, Continuing | 2 | 2018 | 638 | 0.14 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.14 | Why? |
| Review Literature as Topic | 1 | 2017 | 387 | 0.13 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.13 | Why? |
| Education | 1 | 2018 | 434 | 0.13 | Why? |
| Propensity Score | 2 | 2019 | 2690 | 0.13 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.12 | Why? |
| Drug Hypersensitivity | 1 | 2019 | 401 | 0.12 | Why? |
| Epilepsy, Temporal Lobe | 1 | 2012 | 37 | 0.12 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.12 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.12 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.12 | Why? |
| Infant | 8 | 2021 | 30274 | 0.12 | Why? |
| England | 3 | 2021 | 5116 | 0.12 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.12 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.12 | Why? |
| Clinical Protocols | 2 | 2021 | 2734 | 0.12 | Why? |
| Fever | 2 | 2020 | 7795 | 0.12 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.12 | Why? |
| General Practice | 1 | 2020 | 718 | 0.11 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Anti-Infective Agents | 2 | 2018 | 1766 | 0.11 | Why? |
| Counseling | 2 | 2018 | 747 | 0.10 | Why? |
| Molluscum Contagiosum | 1 | 2009 | 11 | 0.10 | Why? |
| Ambulatory Care Facilities | 2 | 2021 | 2063 | 0.10 | Why? |
| Time Factors | 5 | 2021 | 31397 | 0.10 | Why? |
| Public Health Surveillance | 2 | 2021 | 3129 | 0.10 | Why? |
| Physician-Patient Relations | 2 | 2018 | 1266 | 0.10 | Why? |
| Self Care | 1 | 2018 | 918 | 0.10 | Why? |
| Pneumonia | 3 | 2018 | 5652 | 0.10 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.10 | Why? |
| Adult | 13 | 2021 | 244371 | 0.10 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.10 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.10 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.10 | Why? |
| Child | 8 | 2021 | 70012 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.10 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.10 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.09 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.09 | Why? |
| Germany | 2 | 2021 | 9196 | 0.09 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.09 | Why? |
| Spain | 2 | 2017 | 15545 | 0.09 | Why? |
| Behavior Therapy | 1 | 2012 | 235 | 0.09 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.09 | Why? |
| Anti-HIV Agents | 1 | 2021 | 2209 | 0.09 | Why? |
| Symptom Assessment | 2 | 2018 | 4967 | 0.08 | Why? |
| Retrospective Studies | 5 | 2019 | 105322 | 0.08 | Why? |
| Dementia | 1 | 2021 | 1861 | 0.08 | Why? |
| Health Communication | 1 | 2018 | 1120 | 0.08 | Why? |
| Cough | 2 | 2018 | 4891 | 0.08 | Why? |
| Health Education | 1 | 2018 | 1539 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Child, Preschool | 7 | 2021 | 36283 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Delivery of Health Care, Integrated | 1 | 2018 | 1549 | 0.08 | Why? |
| Research | 1 | 2019 | 2115 | 0.08 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.07 | Why? |
| HIV Infections | 2 | 2021 | 11620 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Brain Diseases | 1 | 2017 | 1463 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.07 | Why? |
| Family Practice | 1 | 2012 | 472 | 0.07 | Why? |
| Administration, Inhalation | 2 | 2021 | 1647 | 0.07 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.07 | Why? |
| Acute Disease | 4 | 2018 | 6029 | 0.07 | Why? |
| Communicable Diseases | 1 | 2019 | 2148 | 0.07 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Pediatrics | 1 | 2018 | 2969 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| Longitudinal Studies | 1 | 2016 | 9893 | 0.05 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.05 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Caribbean Region | 1 | 2021 | 349 | 0.05 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.05 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.05 | Why? |
| Trypanosoma brucei brucei | 1 | 2017 | 9 | 0.04 | Why? |
| Erythromycin | 1 | 2017 | 17 | 0.04 | Why? |
| Patient Acceptance of Health Care | 1 | 2016 | 5002 | 0.04 | Why? |
| Trypanosomiasis, African | 1 | 2017 | 31 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| Education, Distance | 1 | 2018 | 4956 | 0.04 | Why? |
| Social Control, Formal | 1 | 2019 | 165 | 0.04 | Why? |
| Moral Obligations | 1 | 2018 | 125 | 0.04 | Why? |
| Publication Bias | 1 | 2017 | 241 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.04 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.04 | Why? |
| Ireland | 1 | 2021 | 1456 | 0.04 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2021 | 1517 | 0.04 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.04 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 952 | 0.04 | Why? |
| Latin America | 1 | 2021 | 1721 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Sweden | 1 | 2021 | 1969 | 0.03 | Why? |
| Societies, Medical | 2 | 2021 | 6907 | 0.03 | Why? |
| Tape Recording | 1 | 2012 | 6 | 0.03 | Why? |
| Community Health Workers | 1 | 2018 | 468 | 0.03 | Why? |
| Population Surveillance | 2 | 2021 | 4967 | 0.03 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Bias | 1 | 2017 | 1109 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2018 | 7972 | 0.03 | Why? |
| Mental Health | 1 | 2018 | 15770 | 0.03 | Why? |
| Obesity | 1 | 2012 | 7388 | 0.03 | Why? |
| Sodium Nitrite | 1 | 2009 | 1 | 0.03 | Why? |
| Cimetidine | 1 | 2009 | 4 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Climate Change | 1 | 2019 | 901 | 0.03 | Why? |
| Potassium Compounds | 1 | 2009 | 8 | 0.03 | Why? |
| Structure-Activity Relationship | 1 | 2017 | 2219 | 0.03 | Why? |
| Salicylic Acid | 1 | 2009 | 10 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Hydroxides | 1 | 2009 | 18 | 0.03 | Why? |
| Virus Diseases | 2 | 2017 | 3779 | 0.02 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.02 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2019 | 29620 | 0.02 | Why? |
| Remission, Spontaneous | 1 | 2009 | 186 | 0.02 | Why? |
| Qualitative Research | 1 | 2021 | 4337 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Sputum | 1 | 2016 | 1720 | 0.02 | Why? |
| Patient Simulation | 1 | 2012 | 338 | 0.02 | Why? |
| Communication | 2 | 2018 | 5206 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.02 | Why? |
| Odds Ratio | 1 | 2019 | 5861 | 0.02 | Why? |
| Neuropsychological Tests | 1 | 2012 | 954 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2016 | 4260 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Povidone-Iodine | 1 | 2009 | 213 | 0.02 | Why? |
| Electronic Health Records | 1 | 2019 | 3492 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2017 | 48226 | 0.02 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.02 | Why? |
| Parents | 1 | 2018 | 2758 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Cluster Analysis | 1 | 2012 | 3001 | 0.02 | Why? |
| Smoking Cessation | 1 | 2012 | 826 | 0.02 | Why? |
| Arrhythmias, Cardiac | 1 | 2017 | 2510 | 0.02 | Why? |
| Smoking | 1 | 2016 | 3358 | 0.02 | Why? |
| Anti-Infective Agents, Local | 1 | 2009 | 520 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.02 | Why? |
| Phytotherapy | 1 | 2009 | 743 | 0.01 | Why? |
| Patient Education as Topic | 1 | 2012 | 1476 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Logistic Models | 1 | 2016 | 9089 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2016 | 5486 | 0.01 | Why? |
| Brain | 1 | 2017 | 5133 | 0.01 | Why? |
| Diet | 1 | 2012 | 2052 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Health Behavior | 1 | 2012 | 4449 | 0.01 | Why? |
| Comorbidity | 1 | 2016 | 34796 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Animals | 1 | 2019 | 78931 | 0.01 | Why? |
| Elementary Particles | 1 | 1947 | 1 | 0.01 | Why? |
| Nuclear Energy | 1 | 1947 | 6 | 0.01 | Why? |